🇺🇸 FDA
Pipeline program

Humanized anti-CD117 Monoclonal Antibody (JSP191)

JSP-CP-003

Phase 1 mab active

Quick answer

Humanized anti-CD117 Monoclonal Antibody (JSP191) for MYELODYSPLASTIC SYNDROME; MDS is a Phase 1 program (mab) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Jasper Therapeutics
Indication
MYELODYSPLASTIC SYNDROME; MDS
Phase
Phase 1
Modality
mab
Status
active

Clinical trials